Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
Failure of a subcutaneous formulation of Vyvgart raises questions about the drug’s future in primary immune thrombocytopenia and beyond.
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.
Against the odds GSK’s Dreamm-7 study yields a positive survival readout.
But, with the end in sight for the CD38 blockbuster, will Johnson & Johnson buy into Genmab’s next-gen project?
Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.